TUBERCIN is an amazing example of development in science and technology at the dawn of the 21st century.
TUBERCIN is a remarkable Immunostimulant that is derived from Mycobacterium Tuberculosis. It is purified and it becomes a safe, non-toxic and non-addictive Immunostimulant.
As an Immunostimulant, TUBERCIN increases the strength in the immune system enabling it to ultimately destroy the cancer cells. Tubercin is effective in strengthening the immune system to eradicate various types of cancer in patients without any side effects. Currently, stages three and four (terminal cancer) are very difficult to combat.
TUBERCIN DOES WORK ON STAGES INCLUDING THREE AND FOUR. Over two thousand patients have been treated with TUBERCIN under strict clinical settings in South Korea at the oldest and very prestigious university hospital in Taegu , Korea , Kyungpook National University Medical School . Today approximately 40 % of these 2000 terminal Cancer patients positively impacted and a significant number has remained cancer free within this 20 year duration. Dr. Tai-Ho Chung the inventor of Tubercin T-5 has published his findings over the last seventeen years in Korean Medical Journals. Dr. Tai-Ho Chung was the former Medical School dean and is currently the Director of the World Health Organization (WHO) Medical Research Center dealing with Hepatitis situated at the Kyungpook National University , Taegu , Korea .
On January 2002, the International Journal of Dermatology, Volume 41. Issue 1., announced the successful treatment of a 77 year old Taegu woman with Acral Lentiginous Melanoma using Tubercin. This woman was diagnosed with terminal Acral Lentiginous Melanoma and her arm was recommended to be amputated to extend her life. She was diagnosed with three—four months to live. She refused amputation and sought Dr. Tai Ho Chung (Inventor) to administer Tubercin. On Dec. 24, 1999 she began treatment with Tubercin and 10 months later the Melanoma cancer disappeared. On December 28, 2000 , an official biopsy was performed and she was declared CANCER FREE .
Over the past ten years, epoch making anticancer agents have continuously been introduced, but the mortality of cancer patients have been rising in the U.S. and the European countries not to mention Japan and Korea . The decisive measure to cope with cancer is surgery.
When the cancer cells spread throughout the body instead of remaining on the original spot, the treatment should take into consideration chemotherapy, radiation therapy and immunotherapy. The drawback of such therapies, however, is they incur damages not only on cancer cells, but also on the normal cells.
Chemotherapy and radiation therapy are not suitable for application on weakened patients, especially those above 70. Historically, various forms of immunotherapy have been performed, falling short of therapeutic expectation. When Bacille calmetteguerin is used as an active no-specific immunotherapeutic agent, however, the patient's prognosis turns better through a simulative action on immune system of the cancer case.
Professor T.H. Chung of Korea extracted carbohydrate complex Tubercin from micro bacterium tuberculosis to be used as immunostimulant. This was meant to activate the T-lymphocyte of the cancer patient to produce lymphokine. This process strengthened and promoted immuno surveillance activities in deficient state and alleviated the pain and prolonged the life of cancer patients.
TUBERCIN is derived from micro bacterium tuberculosis. As an immunostimulant, TUBERCIN strengthens the human body's own immune system and assists the body in seeking out and combating cancer cells. ArTec is able to develop TUBERCIN into a low-cost product to treat cancer patients on an international scale. Salient treatment, through the administration of TUBERCIN, could positively affect thousands of lives in North America . In addition, Europe and Asia have millions of lives at risk each year because of viral diseases such as cancer.
TUBERCIN IS A FINISHED PRODUCT. Tubercin as an inmunostimulant has been administered to human patients in stages three and four of terminal cancer . There have been no indications of any adverse side effects in human trials. There has been encouraging results of patients with TUBERCIN in the last fourteen years. Various forms of cancer were involved and many of the patients survived. Statistically speaking forty percent (40%) is a realistic survival rate among patients experiencing the varying forms of cancer who have been treated with TUBERCIN. Research and Development is complete. Currently Tubercin is in use through compassionate care.
WHAT OTHERS SAY:
ArTec Inc., cites a study that supports essentially how TUBERCIN works in the battle against cancer. Please consult Reuters Health eLine Headlines for. April 25, 2001 which states as follows:
The Immune System can help block, fight cancer - study LONDON (Reuters) - In a finding that could lead to the development of new ways to fight cancer, scientists in the United States " said Wednesday they had firm evidence that the immune system can help prevent tumors. The body's natural defense mechanism helps to fight Infections and other ailments and scientists had suspected it also played a role in defeating cancer cells. Robert Schreiber, of the Washington University School of Medicine in St Louis, and Lloyd Old, of the Ludwig Institute of Cancer Research at memorial Sloan Kettering Cancer Center in New York have now shown that white blood cells called lymphocytes and an immune cell protein known as gamma interferon (IFNg) seek out and destroy cancerous cells. 'This is very exciting because it indicates that immunotherapy has a significant potential use even for the treatment of tumors that are altered by the immunoediting process," said Schreiber.
Also. a press release dated May 14, 2001 from a San Francisco meeting of cancer researchers announced accomplishments have been made, cancer vaccines demonstrate promise of getting the body's immune system to kill tumors the same way it fights off infections. We at ArTec would like to point out that TUBERCIN has no side affects and has been very successful in training T-Cells to attack and kill diseased cells.
NASAL SPRAY:
Utilizing an effective and efficient delivery system for Tubercin is necessary in order to place the product into over the counter market place. The present delivery system is by injections. Needles have a negative impact on consumers, especially if the consumer is not familiar with how to inject oneself property. To attract customers we must have an attractive delivery system that is easy to use and reflects a positive image. ArTec Incorporated has determined that a “Nasal Sprays” is an excellent method for administering Tubercin.
The following statement is from an Article printed in Lycos Health WebMD Search dated July 17, 2001 . By William H. Fray II, PhD, 'The nose contains nerve endings connected directly to two very powerful networks: the olfactory nerves, which control the sense of smell, and the trigeminal nerve, which sends sensations from the face and head to the brain. These nerves provide a: direct shot from the nose to the brain, without stopping in the bloodstream. That means that an immune stimulant can reach the brain in less than 15 minutes, less than half the time it would take if the immune stimulant were injected into a vein. This is important, because immune stimulants that enter the bloodstream are often stopped short before making into the brain by a natural protection mechanism called the blood-brain barrier.
ArTec Inc. has developed a nasal spray which contains Tubercin. The nasal spray will be marketed and utilized as an over the counter product with the intent of providing the following benefits:
1. Pain Management.
2. Enhancement of the Immune System.
3. Prevention.
4. Good Health Management
5. Building of T-cells.
The nasal pump sprayer will provide a precise measured dose delivering a soothing spray of fine mist of the Tubercin. The nasal spray will be safe, natural and an attractive method of distribution of Tubercin without injections.
A review of clinical studies indicate TUBERCIN has no side effects and could possibly be administered in conjunction with other such modalities for the treatment of cancer without any adverse effects. The scientific presumption would be the distinct possibility of a strengthened immunity system and the administration of treatment such as chemotherapy at the later stages of tumor growth would not be impeded by the weakened condition of the terminal cancer patient.
There is recognition that morphine is a trusted pain killer, but in totality it cannot be said that it has no side effects. In the maintaining of patient care, there is the strong possibility that TUBERCIN could be also considered as a candidate for a pain management. The Company's scientists describe TUBERCIN as having the high propensity of deadening the nerve endings in specific areas of the body where cancer has caused erosion and consequently much pain. Certainly Tubercin should be considered for patients who have strong arthritic pains; when administered to an arthritic patient with such pain the pain has eroded. |
